Biopharma | January 11, 2026
InflaRx shifts focus to lead drug, cuts costs by 30% to extend cash runway
InflaRx is streamlining operations and largely discontinuing non-essential activities outside izicopan’s development
InflaRx is streamlining operations and largely discontinuing non-essential activities outside izicopan’s development
ALV-100 is a bifunctional fusion protein combining glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonism with glucagon-like peptide-1 receptor agonism
The decision follows an interim analysis conducted when roughly half of the patients had completed their Day 84 visit
DME is among the most challenging retinal diseases to treat and has long served as a proving ground for therapies that ultimately become first-line standard of care in retinal diseases
The mPTP plays a key role in mitochondrial dysfunction, inflammation, and neuronal death in neurodegenerative diseases
KRAS G12C-mutant advanced or metastatic nonsquamous non-small cell lung cancer
The partnership aims to develop a first-in-class broad-spectrum antifungal to combat life-threatening invasive infections
The acquisition marks a major step in PAI’s strategy to expand domestic pharmaceutical manufacturing
Appointment supports AstraZeneca’s $50 billion US investment and ambition to reach $80 billion in Total Revenue by 2030
After leading AstraZeneca's Oncology areas nationally and internationally, Laura Colón will assume the presidency of AstraZeneca in one of its priority global markets
Subscribe To Our Newsletter & Stay Updated
